# CVRx, Inc.: overview CVRX · Nasdaq · CIK 1235912 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cvrx.md) · [Financials](/companies/cvrx/financials.md) · [Filings](/companies/cvrx/filings.md) · [Insiders](/companies/cvrx/insiders.md) Latest reported revenue: [$15.7m](/filings/0001628280-26-054336.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054336). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.4](/filings/0001104659-25-107378.md) | [15.3 d](/filings/0001104659-26-014708.md) | [12.3](/filings/0001104659-26-059023.md) | [13.6](/filings/0001628280-26-054336.md) | [14.7](/filings/0001104659-25-107378.md) | [16.0 d](/filings/0001104659-26-014708.md) | [14.8](/filings/0001104659-26-059023.md) | [15.7](/filings/0001628280-26-054336.md) | | Gross margin | % | [83.2%](/filings/0001104659-25-107378.md) | [83.2% d](/filings/0001104659-26-014708.md) | [83.5%](/filings/0001104659-26-059023.md) | [84.3%](/filings/0001628280-26-054336.md) | [86.8%](/filings/0001104659-25-107378.md) | [86.3% d](/filings/0001104659-26-014708.md) | [87.2%](/filings/0001104659-26-059023.md) | [87.4%](/filings/0001628280-26-054336.md) | | Operating margin | % | [(97.3%)](/filings/0001104659-25-107378.md) | [(67.0%) d](/filings/0001104659-26-014708.md) | [(108.8%)](/filings/0001104659-26-059023.md) | [(105.8%)](/filings/0001628280-26-054336.md) | [(83.5%)](/filings/0001104659-25-107378.md) | [(69.8%) d](/filings/0001104659-26-014708.md) | [(82.3%)](/filings/0001104659-26-059023.md) | [(82.9%)](/filings/0001628280-26-054336.md) | | Net margin | % | [(98.0%)](/filings/0001104659-25-107378.md) | [(69.4%) d](/filings/0001104659-26-014708.md) | [(111.5%)](/filings/0001104659-26-059023.md) | [(108.4%)](/filings/0001628280-26-054336.md) | [(87.6%)](/filings/0001104659-25-107378.md) | [(74.5%) d](/filings/0001104659-26-014708.md) | [(88.8%)](/filings/0001104659-26-059023.md) | [(89.4%)](/filings/0001628280-26-054336.md) | | Diluted EPS | $ per share | [(0.57)](/filings/0001104659-25-107378.md) | not reported | [(0.53)](/filings/0001104659-26-059023.md) | [(0.57)](/filings/0001628280-26-054336.md) | [(0.49)](/filings/0001104659-25-107378.md) | not reported | [(0.50)](/filings/0001104659-26-059023.md) | [(0.53)](/filings/0001628280-26-054336.md) | | Free cash flow | $m | [(10.4) d](/filings/0001104659-25-107378.md) | [(8.1) d](/filings/0001104659-26-014708.md) | [(12.9)](/filings/0001104659-26-059023.md) | [(8.0) d](/filings/0001628280-26-054336.md) | [(10.0) d](/filings/0001104659-25-107378.md) | [(9.8) d](/filings/0001104659-26-014708.md) | [(12.3)](/filings/0001104659-26-059023.md) | [(8.9) d](/filings/0001628280-26-054336.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.0](/filings/0001558370-23-001114.md) | [22.5](/filings/0001558370-24-000932.md) | [39.3](/filings/0001558370-25-001055.md) | [51.3](/filings/0001104659-26-014708.md) | [56.7](/filings/0001104659-26-014708.md) | | Gross margin | % | [72.1%](/filings/0001558370-23-001114.md) | [77.8%](/filings/0001558370-24-000932.md) | [84.1%](/filings/0001558370-25-001055.md) | [83.8%](/filings/0001104659-26-014708.md) | [85.3%](/filings/0001104659-26-014708.md) | | Operating margin | % | [(199.2%)](/filings/0001558370-23-001114.md) | [(189.3%)](/filings/0001558370-24-000932.md) | [(109.7%)](/filings/0001558370-25-001055.md) | [(116.0%)](/filings/0001104659-26-014708.md) | [(90.5%)](/filings/0001104659-26-014708.md) | | Net margin | % | [(330.5%)](/filings/0001558370-23-001114.md) | [(184.4%)](/filings/0001558370-24-000932.md) | [(104.8%)](/filings/0001558370-25-001055.md) | [(116.9%)](/filings/0001104659-26-014708.md) | [(94.1%)](/filings/0001104659-26-014708.md) | | Diluted EPS | $ per share | [(4.16)](/filings/0001558370-23-001114.md) | [(2.02)](/filings/0001558370-24-000932.md) | [(1.99)](/filings/0001558370-25-001055.md) | [(2.65)](/filings/0001104659-26-014708.md) | [(2.04)](/filings/0001104659-26-014708.md) | | Free cash flow | $m | [(28.9)](/filings/0001558370-23-001114.md) | [(43.4)](/filings/0001558370-24-000932.md) | [(39.6)](/filings/0001558370-25-001055.md) | [(40.5)](/filings/0001104659-26-014708.md) | [(40.8)](/filings/0001104659-26-014708.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cvrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JOHNSON & JOHNSON](/funds/200406.md) | 2026-06-30 | $20.7m | 4,024,861 | | Unchanged | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $10.0m | 1,954,440 | | Reduced −71,643 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.4m | 1,245,459 | | Added +218,900 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $6.3m | 1,233,212 | | Added +526,262 | | [GSK plc](/funds/1131399.md) | 2026-06-30 | $5.2m | 1,007,583 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.7m | 910,576 | | Reduced −734 | | [SILVERCREST ASSET MANAGEMENT GROUP LLC](/funds/1232395.md) | 2026-06-30 | $4.5m | 878,109 | | Added +306,088 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.3m | 440,786 | | Added +13,714 | | [PFM Health Sciences, LP](/funds/1442756.md) | 2026-06-30 | $1.9m | 369,572 | | New +369,572 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.9m | 366,352 | | Added +15,804 | ## Recent filings [All 325 filings](/companies/cvrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 01:30 ET | [SCHEDULE 13D/A](/filings/0001193805-26-001332.md) | Ownership report, active investor, amended | 0001193805-26-001332 | | 2026-09-21 | 20:13 ET | [8-K](/filings/0001104659-26-109304.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-109304 | | 2026-08-24 | 00:00 ET | [SCHEDULE 13D](/filings/0000921895-26-002298.md) | Ownership report, active investor | 0000921895-26-002298 | | 2026-08-11 | 11:09 ET | [8-K](/filings/0001104659-26-093721.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-093721 | | 2026-08-06 | 20:15 ET | [10-Q](/filings/0001628280-26-054336.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054336 | | 2026-08-06 | 20:11 ET | [8-K](/filings/0001104659-26-092005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092005 | | 2026-06-09 | 12:00 ET | [8-K](/filings/0001104659-26-071595.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-071595 | | 2026-06-03 | 20:49 ET | [8-K](/filings/0001104659-26-070139.md) | 5.07 Shareholder vote results | 0001104659-26-070139 | | 2026-05-12 | 12:00 ET | [10-Q](/filings/0001104659-26-059023.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059023 | | 2026-05-11 | 20:10 ET | [8-K](/filings/0001104659-26-058655.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-058655 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-014708.md), filed Feb 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2ce1bcf1-c4ed-480a-9bf5-1e843414342d) ## About the filer - CIK: 1235912 - Tickers: CVRX - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.